D. P. Parkin

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.

D. P. Parkin, Sam Vandenplas, F J Botha et al. · American Journal of Respiratory and Critical Care Medicine · 1997 · 191 citations

Pulmonary Tuberculosis, Allergy, Tuberculosis Prevention +14

The Early Bactericidal Activity of Isoniazid Related to Its Dose Size in Pulmonary Tuberculosis

PETER R. DONALD, FREDERICK A. SIRGEL, FREDERICK J. BOTHA et al. · American Journal of Respiratory and Critical Care Medicine · 1997 · 124 citations

Tuberculosis Prevention, Bactericidal Activity, Antimicrobial Chemotherapy +16

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid

Peter R. Donald, D. P. Parkin, H. I. Seifart et al. · European Journal of Clinical Pharmacology · 2007 · 98 citations

Pharmacological Study, Medicine, Physiology +4

High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids

H. I. Seifart, W. L. G. Gent, D. P. Parkin et al. · Journal of Chromatography B Biomedical Sciences and Applications · 1995 · 98 citations

Biological Fluids, Chemical Measurement, Biochemistry +9

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

Frederick A. Sirgel, Frederik J. H. Botha, D. P. Parkin et al. · Journal of Antimicrobial Chemotherapy · 1993 · 89 citations